Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Immunocytochemistry for ARID1A as a potential biomarker in urine cytology of bladder cancer.

Dugas SG, Müller DC, Le Magnen C, Federer-Gsponer J, Seifert HH, Ruiz C, Savic Prince S, Vlajnic T, Zellweger T, Mertz KD, Bacon JVW, Wyatt AW, Rentsch CA, Bubendorf L.

Cancer Cytopathol. 2019 Aug 6. doi: 10.1002/cncy.22167. [Epub ahead of print]

PMID:
31386310
2.

Cooperation of loss of NKX3.1 and inflammation in prostate cancer initiation.

Le Magnen C, Virk RK, Dutta A, Kim JY, Panja S, Lopez-Bujanda ZA, Califano A, Drake CG, Mitrofanova A, Abate-Shen C.

Dis Model Mech. 2018 Nov 16;11(11). pii: dmm035139. doi: 10.1242/dmm.035139.

3.

Lineage Plasticity in Cancer Progression and Treatment.

Le Magnen C, Shen MM, Abate-Shen C.

Annu Rev Cancer Biol. 2018 Mar;2:271-289. doi: 10.1146/annurev-cancerbio-030617-050224. Epub 2017 Dec 1.

4.

Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer.

Zou M, Toivanen R, Mitrofanova A, Floch N, Hayati S, Sun Y, Le Magnen C, Chester D, Mostaghel EA, Califano A, Rubin MA, Shen MM, Abate-Shen C.

Cancer Discov. 2017 Jul;7(7):736-749. doi: 10.1158/2159-8290.CD-16-1174. Epub 2017 Apr 14.

5.

Identification of an NKX3.1-G9a-UTY transcriptional regulatory network that controls prostate differentiation.

Dutta A, Le Magnen C, Mitrofanova A, Ouyang X, Califano A, Abate-Shen C.

Science. 2016 Jun 24;352(6293):1576-80. doi: 10.1126/science.aad9512.

6.

Optimizing mouse models for precision cancer prevention.

Le Magnen C, Dutta A, Abate-Shen C.

Nat Rev Cancer. 2016 Mar;16(3):187-96. doi: 10.1038/nrc.2016.1. Epub 2016 Feb 19. Review.

7.

Combination of immortalization and inducible death strategies to generate a human mesenchymal stromal cell line with controlled survival.

Bourgine P, Le Magnen C, Pigeot S, Geurts J, Scherberich A, Martin I.

Stem Cell Res. 2014 Mar;12(2):584-98. doi: 10.1016/j.scr.2013.12.006. Epub 2013 Dec 27.

8.

A molecular signature predictive of indolent prostate cancer.

Irshad S, Bansal M, Castillo-Martin M, Zheng T, Aytes A, Wenske S, Le Magnen C, Guarnieri P, Sumazin P, Benson MC, Shen MM, Califano A, Abate-Shen C.

Sci Transl Med. 2013 Sep 11;5(202):202ra122. doi: 10.1126/scitranslmed.3006408. Erratum in: Sci Transl Med. 2013 Sep 18;5(203):203er9.

9.

Characterization and clinical relevance of ALDHbright populations in prostate cancer.

Le Magnen C, Bubendorf L, Rentsch CA, Mengus C, Gsponer J, Zellweger T, Rieken M, Thalmann GN, Cecchini MG, Germann M, Bachmann A, Wyler S, Heberer M, Spagnoli GC.

Clin Cancer Res. 2013 Oct 1;19(19):5361-71. doi: 10.1158/1078-0432.CCR-12-2857. Epub 2013 Aug 22.

10.

Klf4 transcription factor is expressed in the cytoplasm of prostate cancer cells.

Le Magnen C, Bubendorf L, Ruiz C, Zlobec I, Bachmann A, Heberer M, Spagnoli GC, Wyler S, Mengus C.

Eur J Cancer. 2013 Mar;49(4):955-63. doi: 10.1016/j.ejca.2012.09.023. Epub 2012 Oct 22.

PMID:
23089465
11.

Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer.

Mengus C, Le Magnen C, Trella E, Yousef K, Bubendorf L, Provenzano M, Bachmann A, Heberer M, Spagnoli GC, Wyler S.

J Transl Med. 2011 Sep 26;9:162. doi: 10.1186/1479-5876-9-162.

12.

MAGE-A10 is a nuclear protein frequently expressed in high percentages of tumor cells in lung, skin and urothelial malignancies.

Schultz-Thater E, Piscuoglio S, Iezzi G, Le Magnen C, Zajac P, Carafa V, Terracciano L, Tornillo L, Spagnoli GC.

Int J Cancer. 2011 Sep 1;129(5):1137-48. doi: 10.1002/ijc.25777. Epub 2011 Jan 12.

Supplemental Content

Loading ...
Support Center